Literature DB >> 12927820

A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay.

Constance J Glover1, Karen Hite, Renee DeLosh, Dominic A Scudiero, Matthew J Fivash, Lindsey R Smith, Robert J Fisher, Jia Wei Wu, Yigong Shi, Rachael A Kipp, George L McLendon, Edward A Sausville, Robert H Shoemaker.   

Abstract

Resistance to apoptosis is afforded by inhibitor of apoptosis proteins (IAPs) which bind to and inhibit the caspases responsible for cleavage of substrates leading to apoptotic cell death. Smac (or DIABLO), a proapoptotic protein released from the mitochondrial intermembrane space into the cytosol, promotes apoptosis by binding to IAPs, thus reversing their inhibitory effects on caspases. We have developed a high-throughput fluorescence polarization assay utilizing a fluorescein-labeled peptide similar to the "IAP binding" domain of Smac N terminus complexed with the BIR3 domain of X-linked IAP (XIAP) to identify small-molecule mimics of the action of Smac. The IC(50)s of peptides and a tetrapeptidomimetic homologous to the N terminus of Smac demonstrated the specificity and utility of this assay. We have screened the National Cancer Institute "Training Set" of 230 compounds, with well-defined biological actions, and the "Diversity Set" of 2000 chemically diverse structures for compounds which significantly reduced fluorescence polarization. Highly fluorescing or fluorescence-quenching compounds (false positives) were distinguished from those which interfered with Smac peptide binding to the XIAP-BIR3 in a dose-dependent manner (true positives). This robust assay offers potential for high-throughput screening discovery of novel compounds simulating the action of Smac/DIABLO.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12927820     DOI: 10.1016/s0003-2697(03)00389-0

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  8 in total

Review 1.  Caspases: pharmacological manipulation of cell death.

Authors:  Inna N Lavrik; Alexander Golks; Peter H Krammer
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  Synthetic Smac peptide enhances chemo-sensitivity of bladder cancer cells.

Authors:  Jing Wang; Fuqing Zeng; Liang Wang; Zhaohui Zhu; Guosong Jiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-06-19

3.  Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells.

Authors:  Bing Z Carter; Marcela Gronda; Zhiliang Wang; Kate Welsh; Clemencia Pinilla; Michael Andreeff; Wendy D Schober; Adel Nefzi; Gregory R Pond; Imtiaz A Mawji; Richard A Houghten; John Ostresh; Joseph Brandwein; Mark D Minden; Andre C Schuh; Richard A Wells; Hans Messner; Kathy Chun; John C Reed; Aaron D Schimmer
Journal:  Blood       Date:  2005-02-01       Impact factor: 22.113

4.  Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis.

Authors:  Dong Yang; Yongchao Zhao; Amy Y Li; Shaomeng Wang; Gongxian Wang; Yi Sun
Journal:  Breast Cancer Res Treat       Date:  2011-09-07       Impact factor: 4.872

5.  Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.

Authors:  Sean L Petersen; Lai Wang; Asligul Yalcin-Chin; Lin Li; Michael Peyton; John Minna; Patrick Harran; Xiaodong Wang
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

6.  A class of allosteric caspase inhibitors identified by high-throughput screening.

Authors:  Taya Feldman; Venkataraman Kabaleeswaran; Se Bok Jang; Christophe Antczak; Hakim Djaballah; Hao Wu; Xuejun Jiang
Journal:  Mol Cell       Date:  2012-07-12       Impact factor: 17.970

7.  Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system.

Authors:  Yaneth Osorio; Bruno L Travi; Adam R Renslo; Alex G Peniche; Peter C Melby
Journal:  PLoS Negl Trop Dis       Date:  2011-02-15

8.  Development of XIAP Antagonists Based On De Novo 8,5-Fused Bicyclic Lactams.

Authors:  Zhaojun J Sheng; Yiming M Shi; Ximing Xu; Sébastien Bellynck; Kun Zhang; Zhiyun Y Du; Xuetao Xu; François Maurel; Chang-Zhi Dong
Journal:  ChemistryOpen       Date:  2019-01-15       Impact factor: 2.911

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.